Fate Therapeutics, Inc. (FATE) to Release Earnings on Monday
Fate Therapeutics, Inc. (NASDAQ:FATE) is set to release its earnings data on Monday, November 6th. Analysts expect Fate Therapeutics to post earnings of ($0.25) per share for the quarter.
Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative net margin of 887.68% and a negative return on equity of 67.01%. On average, analysts expect Fate Therapeutics to post $-0.97 EPS for the current fiscal year and $-0.96 EPS for the next fiscal year.
Fate Therapeutics, Inc. (FATE) opened at 4.54 on Monday. The company’s market cap is $188.02 million. The company has a 50-day moving average of $4.14 and a 200 day moving average of $3.67. Fate Therapeutics, Inc. has a one year low of $1.80 and a one year high of $5.68.
TRADEMARK VIOLATION NOTICE: “Fate Therapeutics, Inc. (FATE) to Release Earnings on Monday” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/30/fate-therapeutics-inc-fate-to-release-earnings-on-monday.html.
In other Fate Therapeutics news, General Counsel Cindy Tahl sold 8,091 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $3.85, for a total value of $31,150.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $3.87, for a total transaction of $51,180.75. The disclosure for this sale can be found here. Company insiders own 10.88% of the company’s stock.
A hedge fund recently bought a new stake in Fate Therapeutics stock. State Street Corp purchased a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 443,462 shares of the biopharmaceutical company’s stock, valued at approximately $1,437,000. State Street Corp owned about 1.07% of Fate Therapeutics at the end of the most recent reporting period. 64.27% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have commented on FATE shares. Zacks Investment Research cut shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. ValuEngine upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Leerink Swann reiterated an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Friday, September 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $6.79.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.